This study is being performed to look at 3 different dosing schemes of panobinostat in combination with bortezomib and dexamethasone, and to find the optimal dosing regimen for panobinostat.
Here is some information that may help you gain a better understanding of this study and its goals. By learning more about this study, you'll be able to make an informed decision with your doctor.
Study recipients will receive panobinostat, bortezomib, and dexamethasone.
Panobinostat is being studied in patients with relapsed or relapsed/refractory multiple myeloma who have been previously exposed to immunomodulatory agents such as lenalidomide or pomalidomide.
Panobinostat is being studied in three different dosing schemes in order to find the optimal dosing regimen with bortezomib and dexamethasone.
Approximately 240 people in several countries around the world will participate in this study.
Patients will be treated with the study treatment until disease progression, unless they discontinue earlier for other reasons. All patients will eventually be followed for a maximum of 3 years.